Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a report issued on Monday. They currently have a $460.00 target price on the biopharmaceutical company’s stock. BTIG Research’s price target suggests a potential upside of 20.96% from the stock’s previous close.
Several other research analysts also recently issued reports on REGN. Vetr raised Regeneron Pharmaceuticals to a “buy” rating in a research note on Monday, November 21st. Leerink Swann set a $500.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, December 1st. Royal Bank of Canada set a $626.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, December 5th. Chardan Capital raised Regeneron Pharmaceuticals from a “sell” rating to a “neutral” rating and upped their price objective for the company from $300.00 to $350.00 in a research note on Monday, December 12th. Finally, Robert W. Baird reaffirmed a “positive” rating and issued a $379.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, December 12th. Fourteen analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $434.97.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 380.29 on Monday. The stock has a 50 day moving average of $371.86 and a 200 day moving average of $379.60. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $452.96. The company has a market cap of $40.11 billion, a price-to-earnings ratio of 49.39 and a beta of 1.44.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.03 by $0.01. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The company earned $1.23 billion during the quarter, compared to the consensus estimate of $1.30 billion. During the same quarter in the prior year, the firm posted $2.83 earnings per share. The firm’s revenue was up 11.7% compared to the same quarter last year. Equities research analysts predict that Regeneron Pharmaceuticals will post $12.95 earnings per share for the current fiscal year.
Your IP Address:
In other news, major shareholder Sanofi bought 87,298 shares of the business’s stock in a transaction that occurred on Wednesday, January 11th. The shares were bought at an average cost of $369.71 per share, for a total transaction of $32,274,943.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 10.40% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 6.6% in the third quarter. Capital World Investors now owns 7,810,538 shares of the biopharmaceutical company’s stock worth $3,139,992,000 after buying an additional 483,912 shares during the last quarter. State Street Corp raised its stake in Regeneron Pharmaceuticals by 2.2% in the fourth quarter. State Street Corp now owns 3,240,549 shares of the biopharmaceutical company’s stock worth $1,189,574,000 after buying an additional 68,675 shares during the last quarter. BlackRock Fund Advisors raised its stake in Regeneron Pharmaceuticals by 3.1% in the third quarter. BlackRock Fund Advisors now owns 2,290,395 shares of the biopharmaceutical company’s stock worth $920,785,000 after buying an additional 68,436 shares during the last quarter. Jennison Associates LLC raised its stake in Regeneron Pharmaceuticals by 4.5% in the third quarter. Jennison Associates LLC now owns 2,122,148 shares of the biopharmaceutical company’s stock worth $853,146,000 after buying an additional 91,223 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. raised its stake in Regeneron Pharmaceuticals by 0.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 2,017,842 shares of the biopharmaceutical company’s stock worth $811,213,000 after buying an additional 7,547 shares during the last quarter. 68.83% of the stock is owned by institutional investors and hedge funds.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/regeneron-pharmaceuticals-regn-buy-rating-reaffirmed-at-btig-research/1708945.html
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.